BD (BDX) Q3 2026 earnings review
First Full Quarter of 'New BD' Delivers Broad Rebound
In its first full quarter since spinning off the Life Sciences division, BD demonstrated the power of its pure-play medtech focus. Revenue grew a solid 5.4% YoY to $5.0 billion, beating expectations with broad-based growth across all four segments. The standout was BioPharma Systems, which reversed its prior-quarter contraction to post 6.6% growth as vaccine headwinds eased and GLP-1 tailwinds accelerated. Free cash flow surged 44.6% to $1.7 billion, funding management's aggressive capital return strategy. Confident in the momentum, BD raised the midpoint of its FY26 Adjusted EPS guidance to $12.67 and expects revenue at the high end of its range.
🐂 Bull Case
BioPharma Systems swung from a 1.8% decline in Q2 to a 6.6% increase in Q3. With over 80 GLP-1 biosimilar deals signed, this segment is returning to its role as a high-margin growth engine.
Year-to-date free cash flow jumped 45% to $1.7 billion. Combined with the $4B cash infusion from the Waters transaction, BD's aggressive share repurchases ($2B ASR in Q1/Q2) are heavily compounding EPS growth.
🐻 Bear Case
While mitigated by the BD Excellence program, tariffs remain a structural cost headwind (costing ~160 bps of gross margin in H1). FY27 will require further pricing actions to offset expected resin and oil inflation.
Management previously warned that the year-over-year revenue headwind from lapping record Alaris pump installations will double from 100 bps in FY26 to 200 bps in FY27, which could mask underlying core growth next year.
⚖️ Verdict: 🟢
Bullish. The strategic pivot to a pure-play medtech ('New BD') is working. By successfully managing isolated headwinds (China VBP, vaccines) while aggressively buying back cheap shares and driving margin via the BD Excellence program, BD is establishing a highly reliable compound-growth formula.
Key Themes
BioPharma Reversing from Laggard to Leader
BioPharma Systems (formerly Pharmaceutical Systems) reversed course dramatically, accelerating from a 1.8% decline in Q2 to 6.6% growth ($670M) in Q3. This confirms management's prior assertions that vaccine demand declines were a transitory, isolated headwind. With biologics now representing over 55% of segment revenue and the company securing over 80 deals for GLP-1 biosimilar delivery devices, this segment is back on track toward its $1 billion target by the end of the decade.
BD Excellence Cost-Out Offsetting Macro Headwinds
The 'BD Excellence' operating model continues to be the company's margin engine. By driving an estimated 8% productivity improvement and consolidating a bloated manufacturing network (targeting under 50 plants), BD is achieving a $150M+ run rate on its $200M cost-out plan. This structural efficiency is critical, as it is single-handedly allowing the company to absorb massive macro tariff headwinds while still expanding adjusted operating margins and funding R&D.
Strong Double-Digit Platform Execution
Targeted commercial investments are paying off. Advanced Patient Monitoring (APM), a key sub-segment of Connected Care, continues to see robust demand following its acquisition. More broadly, high-growth platforms like PureWick, advanced tissue regeneration, and pharmacy automation (Pyxis Pro conversions) are consistently delivering double-digit growth, systematically shifting BD's portfolio mix toward higher-margin, higher-growth markets.
Lingering Tariffs and Input Cost Inflation
Macroeconomic pressures persist. Tariffs created a massive 370 basis point headwind to EPS growth in the original FY26 guidance and dragged down gross margins by ~160 bps in the first half of the year. While FY26 oil and resin costs are largely hedged, management previously signaled that FY27 will see elevated raw material costs, forcing BD to lean heavily on pricing power and further cost-cutting to defend margins.
FY27 Alaris 'Grow-Over' Cliff
While current results are strong, the market must prepare for a known headwind: the Alaris pump remediation cycle. Management previously telegraphed that the revenue drag from lapping peak Alaris installations will accelerate from a 100 basis point drag in FY26 to a 200 basis point drag in FY27. This mathematical headwind will suppress reported top-line numbers next year, even if the underlying business remains healthy.
Monitoring the ChloraPrep FDA Warning Letter
In Q2, BD disclosed an FDA warning letter for its El Paso facility leading to a voluntary 3-week US ship hold on ChloraPrep and PurePrep products. While management projected no long-term safety signals or material financial damage, investors should monitor Q4 results closely to ensure no unexpected market share losses or extended regulatory remediation costs materialized in the Medical Essentials segment.
Expanding the Interventional Portfolio via Innovation
BD launched the Elyra Thulium Fiber Laser System in Q3, expanding its kidney stone care portfolio. This specific innovation highlights the company's shift toward high-acuity, workflow-enhancing equipment in the Urology space, further supporting the Interventional segment's strong 6.4% YoY growth this quarter.
Other KPIs
Accelerating significantly. YTD free cash flow grew 44.6% YoY from $1.19 billion to $1.73 billion, driven by stronger net income from continuing operations and tight capital expenditure controls (CapEx slightly down YoY to $376M). This robust cash generation heavily de-risks the company's aggressive share buyback strategy.
Stable and compounding. The largest segment grew 4.5% as reported (3.2% FXN), driven by steady utilization of Medication Delivery Solutions ($1.16B, +2.8%) and accelerating momentum in Specimen Management ($511M, +8.7%).
Reversing sharply upward, increasing 162.9% YoY from $277 million. This massive jump reflects the heavy upfront costs (including $450M in non-cash asset impairment charges taken in Q2) required to execute the BD Excellence network rationalization and the Life Sciences spin-off. While GAAP earnings take a hit, this paves the way for higher adjusted margins in FY27.
Guidance
Accelerating. Management raised the lower end of the range (previously $12.52 to $12.72), pushing the midpoint up by 5 cents. This reflects high confidence in the second-half margin profile and the accretive nature of the recent $2B share repurchase program.
Stable to Accelerating. The company maintained its 'low single-digit plus' GAAP growth range but explicitly stated it expects to land toward the high end of this range. FX is expected to provide an approximate 100 basis point tailwind.
Key Questions
Alaris Transition in FY27
With the expected 200 bps headwind from Alaris lapping in FY27, what specific commercial initiatives or product launches are you relying on to bridge the gap and maintain consolidated mid-single-digit growth next year?
Tariff and Inflation Mitigation
As current oil and resin hedges roll off in FY27, how much pricing power does BD realistically have to offset these raw material costs, versus relying strictly on internal BD Excellence cost-cutting?
ChloraPrep Ship Hold Resolution
Did the 3-week voluntary ship hold for ChloraPrep in Q2 result in any permanent market share losses to competitors, and has the FDA completely cleared the El Paso facility following the warning letter?
M&A vs Buybacks Post-Spin
Given the massive acceleration in free cash flow and the recent $2B ASR, is the current capital allocation strategy permanently skewed toward buybacks over tuck-in M&A, or is the M&A pipeline currently lacking attractive valuations?